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Abstract: OBJECTIVES To evaluate the changes in disease-related biomarkers and safety of paquinimod,
an oral immunomodulatory compound, in patients with systemic sclerosis (SSc). METHODS In this open-
label, single-arm, multicenter study, SSc patients with a rapidly progressive disease received paquinimod
for 8 weeks. Blood and skin biopsies were collected at baseline, during treatment, and at follow-up
for the analyses of type I interferon (IFN) activity, chemokine (C-C motif) ligand 2 (CCL2), and the
number of myofibroblasts. The safety of paquinimod was evaluated throughout the study. RESULTS
Nine SSc patients were enrolled and completed the study treatment with paquinimod at 3 mg/day for
8 weeks. After the treatment, a reduction of type I IFN activity in the plasma from one patient with
elevated baseline IFN activity was recorded. A trend towards reduced IFN activity in the skin after
treatment was also observed in patients. The serum level of CCL2 was reduced in 7 of 9 patients after
paquinimod treatment. There was a median reduction of 10% of the number of myofibroblasts in skin
biopsies at week 8 compared to baseline. No change in modified Rodnan skin score and quality of life
was detected in the study. Reported adverse events (AEs) were mild to moderate and expected with the
most common being arthralgia (n = 3) and headache (n = 3), and C-reactive protein (CRP) increase.
CONCLUSIONS Analysis of biomarkers before and after treatment suggest reduced type I IFN activity
and reduced number of myofibroblasts in lesional skin. Paquinimod was overall well tolerated with mild
to moderate and expected AEs. TRIAL REGISTRATION ClinicalTrials.gov, NCT01487551 . Registered
on 7 September 2011.
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Abstract
Objectives: To evaluate the changes in disease-related biomarkers and safety of paquinimod, an oral immunomodulatory
compound, in patients with systemic sclerosis (SSc).
Methods: In this open-label, single-arm, multicenter study, SSc patients with a rapidly progressive disease received
paquinimod for 8 weeks. Blood and skin biopsies were collected at baseline, during treatment, and at follow-up for the
analyses of type I interferon (IFN) activity, chemokine (C-C motif) ligand 2 (CCL2), and the number of myofibroblasts. The
safety of paquinimod was evaluated throughout the study.
Results: Nine SSc patients were enrolled and completed the study treatment with paquinimod at 3mg/day for 8 weeks.
After the treatment, a reduction of type I IFN activity in the plasma from one patient with elevated baseline IFN activity was
recorded. A trend towards reduced IFN activity in the skin after treatment was also observed in patients. The serum level of
CCL2 was reduced in 7 of 9 patients after paquinimod treatment. There was a median reduction of 10% of the number of
myofibroblasts in skin biopsies at week 8 compared to baseline. No change in modified Rodnan skin score and quality of
life was detected in the study. Reported adverse events (AEs) were mild to moderate and expected with the most
common being arthralgia (n = 3) and headache (n = 3), and C-reactive protein (CRP) increase.
Conclusions: Analysis of biomarkers before and after treatment suggest reduced type I IFN activity and reduced number
of myofibroblasts in lesional skin. Paquinimod was overall well tolerated with mild to moderate and expected AEs.
Trial registration: ClinicalTrials.gov, NCT01487551. Registered on 7 September 2011
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Introduction
Systemic sclerosis (SSc) is a rare autoimmune connective
tissue disease characterized by vascular manifestations,
immune dysfunction, and fibrosis involving multiple
organs, especially the skin, lungs, gastrointestinal tract,
and heart, which can lead to severe organ dysfunction
[1]. There are two subgroups of SSc, limited cutaneous
and diffuse cutaneous, that are clinically differentiated
by the extent of skin involvement. Currently, there is no
cure for SSc, and the morbidity and mortality are high
[2–4]. Existing treatments are focused on controlling
symptoms and preventing complications [5]. Thus, there
is a continuing high unmet medical need for new tar-
geted therapies in SSc.
The pathogenesis of SSc is complex, and until today
poorly understood, but the immunological activity in
SSc is suggested to be the key stimulator of fibrosis and
vascular abnormalities [6]. High concentrations of cytokines
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and chemokines, infiltration of mononuclear cells in af-
fected organs, and production of autoantibodies in SSc pa-
tients have been observed [7, 8]. The importance of the
immune system is further supported by the fact that the
only treatment to date that has shown significant and long-
term survival benefit is autologous stem cell transplantation
[9]. In recent years, a role for the innate immune system in
the pathogenesis of SSc is increasingly recognized [10]. This
is supported by studies showing that a subgroup of SSc pa-
tients displays activation of type I interferons (IFN), key
regulators of the innate immune system in SSc patients
[11–14], and an increased number of macrophages and
monocytes in the blood and in the skin compared to
healthy individuals [7, 15]. Altogether, this suggests that tar-
geting of the innate immune system might provide signifi-
cant benefits in the treatment of SSc.
Paquinimod (ABR-215757) is an oral small-molecule
drug that belongs to the quinoline-3-carboxamide deriva-
tives, a class of compounds with immunomodulatory prop-
erties [16]. It is closely related to laquinimod, which has
demonstrated clinical efficacy in phase 3 studies in multiple
sclerosis (MS) [17, 18]. The S100A9 protein has been iden-
tified as a target molecule for paquinimod [19], and a pro-
inflammatory role for S100A9 is supported by elevated
S100A9 serum levels and tissues in several autoimmune
and inflammatory diseases, including SSc [20–22].
The effect of paquinimod has been demonstrated in
several in vivo models of inflammation and autoimmune
disorders, such as MS, systemic lupus erythematosus
(SLE), rheumatoid arthritis (RA), and atherosclerosis,
suggesting that paquinimod targets a general mechanism
in autoimmunity and inflammation [23–25]. Recently,
paquinimod showed evidence for anti-fibrotic activity in
the tight skin 1 mouse model of SSc and in a mouse
model of liver fibrosis [26, 27].
Previous clinical experience from treatment with paqui-
nimod comes from phase 1 studies in healthy subjects and
SLE patients [24] and an exploratory study in SLE patients
with mild active disease [28]. These studies showed that
paquinimod was well tolerated with mild to moderate and
transient adverse events in doses up to 6mg/day.
We report herein the outcome of an open-label clin-
ical study in SSc patients treated with paquinimod (Clin-
icalTrials.gov Identifier: NCT01487551). The main
objective of this study was to evaluate the changes in
disease-related biomarkers during paquinimod treat-
ment. Secondary objectives were to assess the safety and
tolerability, disease activity, quality of life (QoL), and
plasma levels of paquinimod.
Methods
Study design and treatment
This was an open-label, single-arm, multicenter study
with the primary objective to evaluate the changes in
disease-related biomarkers in skin biopsies and in serum
or plasma from SSc patients treated with paquinimod.
Secondary objectives included safety, disease activity,
QoL, and pharmacokinetics.
In total, 9 patients were included in the study from
November 2011 to February 2013. All patients fulfilled
the 1980 American College of Rheumatology (ACR) cri-
teria for SSc [29]. The inclusion criteria included posi-
tive antinuclear antibodies (ANA), modified Rodnan
skin score (mRSS) of ≥ 16 with skin lesions on one or
both forearms, and rapidly progressive disease defined as
skin thickness progression rate ≥ 40 [30] since the onset
of skin involvement or involvement of at least two new
sites or progression by at least two points in at least two
anatomical sites as defined by the mRSS [31]. Patients
with SSc manifestations such as severe interstitial lung
disease with vital capacity below 60% predicted, pulmon-
ary arterial hypertension, or scleroderma renal crisis
were excluded from the study. Details of the in- and ex-
clusion criteria can be found in the study protocol pro-
vided as an additional file (see Additional file 1).
Patients received daily oral doses of 3.0 mg of paquini-
mod, supplied as 1.5-mg hard gelatin capsules, for 8
weeks. The dose of 3 mg daily was chosen after consider-
ing previous work in SLE where 4.5 and 6mg daily re-
sulted in somewhat more side effects [32]. Allowed
concomitant treatments included low-dose corticoste-
roids at doses equivalent to < 10 mg prednisolone/day
(stable for 8 weeks prior to the first dose and throughout
the study), proton pump inhibitors, and vasodilators, ex-
cept for endothelin receptor antagonists. Concomitant
treatment with potentially disease-modifying agents such
as rituximab, mycophenolate mofetil, methotrexate,
cyclophosphamide, azathioprine, or other immunosup-
pressive drugs was not allowed.
Blood samples and skin biopsies were taken for various
biomarkers, paquinimod exposure, and safety parame-
ters. The blood samples were taken at all scheduled
visits, i.e., week − 2 (screening), week 0 (baseline), week
2, week 4, week 8 (end-of-treatment), and week 12 (fol-
low-up). Two punch skin biopsies, with a diameter of 4
mm, were taken from lesional skin 15 ± 2 cm proximal
from the styloid process of the ulna on the forearm at
baseline and at the end of treatment (EOT) at week 8.
The two biopsies were taken as closely as possible to
each other (distance 2–5 mm). One of the biopsies was
transferred to RNAlater (Ambion, Life Technologies,
Carlsbad, CA) for further gene expression analysis. The
other biopsy was fixed in paraformaldehyde for immu-
nohistochemistry analyses.
Pharmacokinetic assessments
Pre-dose plasma samples were taken at all scheduled
visits, from baseline to follow-up. The plasma
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concentration of paquinimod was determined using an
internally validated method at Active Biotech AB which
is based on protein precipitation, stable isotope dilution,
and liquid chromatography mass spectrometry/mass
spectrometry (LC-MS/MS). In brief, plasma samples
were precipitated by the addition of two volumes of
acidified acetonitrile containing a stable isotope-labeled
paquinimod internal standard containing six 13C atoms.
Samples with anticipated concentrations above the
upper limit of quantification were diluted 5 times with
blank human heparin plasma. After centrifugation of the
samples, the supernatant was directly injected onto a 2.1
× 30mm reversed-phase LC column (Symmetry Shield
RP18, Waters, USA) and eluted with a fast LC gradient.
The analytes were then quantified by a triple quadrupole
mass spectrometer operated in positive multiple reaction
monitoring (MRM) mode using the mass transitions m/
z 351.2 → 122.2 for ABR-215757 and 357.2 → 128.2 for
the internal standard.
Cytokine analysis in blood
The analysis of chemokine (C-C motif) ligand 2 (CCL2)
in the serum was performed using a Quantikine®
enzyme-linked immunoassay kit (R&D Systems, Minne-
apolis, MN) according to the manufacturer’s instruc-
tions. Samples were run in duplicates.
The plasma type I interferon (IFN) activity was mea-
sured as described earlier [14, 32]. In brief, the amnion-
derived WISH cell line [33] (American Type Culture
Collection, Manassas, VA) was incubated with plasma
samples for 6 h and then lysed by the addition of lysis
mixture (Panomics Inc., Fermont, CA). The cell lysates
were analyzed by using a Luminex 200™ System (Lumi-
nex Corporation) for mRNA expression of six different
type I IFN inducible genes (interferon-induced protein
with tetratricopeptide repeats 1 (IFIT1), interferon-
stimulated gene 15 (ISG15), lymphocyte antigen 6 family
member E (LY6E), MX dynamin-like GTPase 1 (MX1),
2′-5′-oligoadenylate synthetase 1 (OAS1), and peptidyl-
prolyl isomerase B (PPIB) and three housekeeping genes
(beta-2-microglobulin (B2M), eukaryotic translation ini-
tiation factor 2 alpha kinase 2 (EIF2AK2), and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH))
using the Procarta Cytokine Assay Kit (Panomics), ac-
cording to the manufacturer’s instructions. To calculate
the type I IFN activity, the individual mRNA expression
of each of the type I IFN-regulated genes were divided
by the combined mean expression of the three house-
keeping genes to obtain a relative expression. The
relative expression for each individual sample was nor-
malized to the relative mRNA expression of the genes in
unstimulated WISH cells. The IFN activity of each
plasma sample was then calculated as the mean normal-
ized expression for the six IFN-induced genes. For
plasma samples lacking type I IFN activity, a score of 1
was given.
Analysis of gene expression in the skin by quantitative
real-time PCR
Total RNA from the biopsies was extracted using the
NucleoSpin RNA II extraction system (Machery-Nagel,
Düren, Germany). cDNA was produced by using the
RT2 First Strand Kit (Qiagen Sciences, Germantown,
MD). Gene expression analyses were performed by vali-
dated RT2 qPCR Primer Assays (Qiagen) for interferon
alpha-inducible protein 6 (IFI6) (RefSeq. NM_002038.3),
inducible alpha protein 27 (IFI27) (RefSeq. NM_
005532.3), interferon-induced protein 44 (IFI44) (RefSeq.
NM_006417.4), interferon-induced protein 44 like (IFI44L)
(RefSeq. NM_006820.2), radical s-adenosyl methionine
domain containing 2 (RSAD2) (RefSeq. NM_080657.4),
chemokine (C-C motif) ligand 2 (CCL2) (RefSeq. NM_
NM_002982), and chemokine (C-C motif) receptor 2
(CCR2) (RefSeq. NM_001123396), according to the manu-
facturer’s instructions on a Thermocycler CFX96 instru-
ment (Bio-Rad). The quantification of the relative changes
in the gene expression from baseline to week 8 was calcu-
lated using the 2−ΔΔCt method using beta-actin (ACTB)
(RefSeq. NM_001101.3) for normalization.
Immunohistochemistry
The skin biopsies were fixed in paraformaldehyde for 6 h
and then put in 50% ethanol and stored at room
temperature (15–25 °C). Samples were dehydrated ac-
cording to the standard procedures before embedding in
paraffin.
Myofibroblasts were detected in paraffin-embedded
tissue sections of skin biopsies by incubation with monoclo-
nal anti-alpha smooth muscle actin (anti-αSMA) antibodies
(clone 1A4, dilution1:1000, Sigma-Aldrich, Steinheim,
Germany) without specific antigen retrieval. The expression
was visualized with horseradish peroxidase-labeled second-
ary antibodies and 3,3-diaminobenzidine tetrahydrochloride
(DAB) (Sigma-Aldrich). Monoclonal mouse IgG antibodies
(Calbiochem, San Diego, CA) were used as controls. The
number of myofibroblasts was determined by a blinded,
experienced reviewer in 10 random areas of each section by
two independent staining series for each biopsy.
Safety assessment
Safety variables monitored throughout the study included
adverse events (AEs), clinical laboratory parameters, vital
signs, physical examination, and electrocardiogram (ECG).
AEs were classified by the local investigator depending on
seriousness (AE or serious adverse event (SAE)), causality/
relationship (probable/possible/unlikely), and severity
grading (mild, moderate, severe) to describe the maximum
intensity of the adverse. All local hospital laboratories used
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for the safety laboratory evaluations were accredited and
certified. Laboratory parameters included hematology,
clinical chemistry, coagulation, and urinalysis. The ECGs
were centrally evaluated by an independent cardiologist.
Disease activity and QoL
Clinical assessments included the mRSS and number of
digital ulcers assessed at screening, baseline, week 4,
week 8 (end of treatment), and week 12 (follow-up). For
the mRSS, the thickness of the skin was assessed at 17
regions of the body, each scored from 0 to 3 (normal to
severe) resulting in the highest theoretical mRSS score
of 51 [31]. QoL was assessed using the Short Form (36)
Health Survey (SF-36) and Scleroderma Health Assess-
ment Questionnaire (SHAQ) at baseline, week 8, and
week 12. SF-36 consists of 36 questions about health
resulting in two summary measures, physical and mental
component summaries. The SHAQ scale consists of
three parts, disability index (HAQ-DI) that via a ques-
tionnaire assesses disability, a pain scale that assesses
pain, and a number of disease-related questions.
Statistical analysis
The primary endpoint for this study was changes in bio-
markers during treatment. For the statistical analyses, p-
values were calculated using the non-parametric two-
sided Wilcoxon signed rank test at a 5% significance
level. The reported p-values for the biomarkers were not




Nine SSc patients meeting the inclusion criteria were en-
rolled, and all completed the study including an 8-week
treatment with paquinimod at 3 mg/day and a 4-week
follow-up. All patients had rapidly progressive disease
and were ANA-positive, and the patient without RNA-
polymerase III or topoisomerase I antibodies was ANA-
positive with a nucleolar immunofluorescence pattern.
Baseline demographics and characteristics of the patients
are summarized in Table 1. Three patients had lung fi-
brosis on HRCT, and 7 patients were considered to have
Table 1 Baseline characteristics
Parameter Mean (SD) Median Range
Age (years) 48 (12) 47 28–67
Weight (kg) 65 (9) 66 50–79
Height (cm) 169 (8) 170 157–184
Sex
Female (n) 7 – –
Male (n) 2 – –
Disease duration (months) since
Onset of Raynaud’s phenomenon 32 (38) 17 2–120
Onset of skin involvement 20 (16) 16 8–58
mRSS 28 (10) 25 19–46
QoLa
HAQ-DI 1.1 (0.6) 1.0 0.5–2.2
SF-36 Physical component sum 35 (12) 37 17–48
Parameter Yes No Unknown
Antinuclear antibody (ANA) positive (n) 9 0 0
Anti-RNA polymerase III positive (n) 3 5 1
Anti-topoisomerase I positive (n) 5 3 1
Lung fibrosis (by high-resolution CT) (n) 3 6 0
Pitting scars (n) 4 5 0
Digital ulcers (n) 1 8 0
Ongoing corticosteroid treatmentb (n) 3 6 0
Previous immunosuppressive treatment (n) 0 9 0
SD standard deviation
aQoL-HAQ-DI is a disability index ranging from 0 to 3 where 0 means that certain activities can be done without difficulty and 3 means that these activities
cannot be done at all. SF-36 is a health index where 0 means maximum disability and 100 means no disability. The SF-36 Physical component sum is a calculated
score based on different questions related to physical health
bIndication was joint involvement in all 3 patients and doses equivalent to < 10 mg prednisolone per day
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gastrointestinal involvement. Five had musculoskeletal
involvement, whereas none had myocardial or renal
involvement.
Paquinimod plasma concentrations
The analyses of plasma concentrations showed that all
patients in the study were well exposed to paquinimod.
The average pre-dose concentration after 8 weeks of
treatment was 4650 ± 436 nmol/L (mean ± standard error
of the mean). All patients reached approximate steady-
state concentrations within 2 weeks of treatment (Fig. 1)
which is in accordance with the half-life of approximately
80 h reported previously in SLE patients [24].
Biomarkers in the blood and skin
Type I IFN activity
The activity of type I IFNs was analyzed in the plasma
from the patients at baseline, at weeks 4 and 8, and at
follow-up at week 12 by using a sensitive functional cell-
based assay [24]. As shown in Fig. 2A, elevated levels of
type I IFN activity in the plasma were detected in one of
the nine patients at baseline. A clear reduction was evi-
dent already after 4 weeks of treatment in this specific
patient, and the activity then remained low throughout
the whole treatment period. An increase was recorded at
12 weeks follow-up in this patient, supporting that the
observed effect is linked to the paquinimod treatment.
Furthermore, the expression of 5 different type I IFN
responsive genes IFI44, IFI44L, IFI6, IFI27, and RSAD2,
reported to be upregulated in SSc skin [13] was ana-
lyzed. In the present study, the mRNA level of each gene
was measured in the skin biopsies at baseline and after
8 weeks of treatment. For each of these genes, a numer-
ical decrease in mean mRNA levels during treatment
was observed in the whole patient population, which did
not reach statistical significance due to the low patient
numbers (Fig. 2B). In the patient with elevated IFN ac-
tivity in the plasma, 4/5 IFN responsive genes (IFI44,
IFI44L, IFI6, and IFI27) were reduced after treatment
with paquinimod. In this specific patient, the level of
gene expression of all 5 IFN-responsive genes at baseline
was elevated compared to the other patients (data not
shown), suggesting that there is a correlation between
IFN signature in lesional tissue and peripheral blood in
SSc patients as earlier reported [34].
Analysis of CCL2 and CCR2
CCL2 is a chemokine that is involved in promoting in-
flammation and tissue fibrosis in SSc [35, 36]. Figure 3
shows a decrease in the CCL2 serum level from baseline
to week 8 in 7 of the 9 patients, the median reduction
for all patients was 18% (p = 0.07). However, even
though there was no clear correlation between change in
CCL2 gene expression in the skin biopsies and changes
observed for CCL2 in the serum after paquinimod treat-
ment, a decrease of mRNA levels in the skin was ob-
served in 5 out of 9 patients after 8 weeks of treatment
(data not shown). Interestingly, the two patients without
a decrease of serum CCL2 neither had a downregulation
of CCL2 mRNA levels in the skin.
CCR2, the major receptor for CCL2, which has been
found at high levels in skin biopsies from SSc patients
[37], was also analyzed, and the results showed a down-
regulation of the CCR2 mRNA levels in the skin in 8 out
Fig. 1 Plasma levels of paquinimod in each individual patient were analyzed at weeks 2, 4 and 8, and at follow-up week 12, by using LC-MS/MS
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of the 9 patients (Fig. 4). The mean fold change was 0.59
(p = 0.019).
Myofibroblasts in the skin
Immunohistochemical assessment of the number of
αSMA expressing myofibroblasts, the main producer of
extracellular matrix proteins, in skin samples from the
patients at baseline and after 8 weeks of treatment with
paquinimod demonstrated a mild reduction of the num-
ber of myofibroblasts in the majority of patients (Fig. 5).
The statistical analysis demonstrated a reduction in
myofibroblast count of 8% at week 8 compared to base-
line (p = 0.023). There was no correlation between skin
score at the biopsy site and myofibroblast count.
Safety and adverse events
The study drug was generally well tolerated, and all nine
patients completed the study at 3.0 mg/day. Adverse
events were reported in all 9 patients. All AEs were of
mild to moderate severity (Table 2). The AEs assessed as
related to study treatment and recorded in more than
one patient were arthralgia, myalgia, diarrhea, and
headache. One patient interrupted treatment for 7 days
due to pruritus, an AE of moderate intensity that also
was assessed as possibly related to the treatment. There
was one serious AE with peripheral ischemia considered
unlikely related to the study drug. All reported AEs oc-
curring more than once during the study are presented
in Table 2 by system organ class and by preferred term
(according to the medical dictionary for regulatory activ-
ities (MedDRA)).
The laboratory parameters mainly concerned transient
increases in inflammatory markers such as C-reactive
protein (CRP) and erythrocyte sedimentation rate (ESR).
All patients experienced increased CRP levels during
treatment. The mean levels of CRP increased from 9.6
to 22mg/L from baseline to week 2 when paquinimod
plasma concentrations had reached an approximate
steady state. The levels then slightly decreased to a mean
of 20 mg/L at week 8 and 14mg/L at follow-up. For two
of the patients, the increased CRP levels were considered
by the investigator to be clinically significant and were
reported as AEs of mild intensity, one as nasopharyngi-
tis, and the other as CRP increase. The increases in
Fig. 2 A Type I IFN activity in plasma in each individual patient was analyzed at baseline, weeks 4 and 8, and at follow-up week 12, by using a
functional receptor assay. B The gene expression of five type I IFN responsive genes, IFI44, IFI44L, IFI6, IFI27, and RSAD2, in the skin was analyzed
by real-time PCR. The forest plot shows mean fold changes (log2) of each gene after 8 weeks of treatment. The dashes indicate mean fold
changes (log2) after 8 weeks of treatment with paquinimod, and the horizontal bars show 95% CIs
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inflammatory markers were observed during the first
treatment weeks and declined towards the end of the
study, similar to the reported laboratory parameters in
SLE patients treated with paquinimod [19]. Transient,
slight (< 2 fold) increases in hepatic enzymes such as ala-
nine transaminase (ALT), aspartate transaminase (AST),
and alkaline phosphatase (ALP) were also observed dur-
ing the study. This was not accompanied by any increase
in bilirubin.
No major changes in the vital signs were observed.
Seven patients lost weight during the study. Six patients
lost from 1 to 3 kg, whereas 1 patient lost 7.1 kg from
baseline. However, this patient started to lose weight
already between screening and baseline (− 1.5 kg).
Disease activity and QoL
There were only minor, non-statistically significant,
changes in mRSS in this study as expected in a short
Fig. 4 Changes in normalized gene expression of CCR2 in the skin. The mean fold reduction was 0.59 (p = 0.019) (shown in red) after 8 weeks
of treatment
Fig. 3 Changes in the levels of CCL2 in the serum during the whole study in each individual patient. The recorded baseline values ranged between
427 and 1309 pg/mL. A reduction was observed in 7 out of 9 patients during treatment; the mean (shown in red) reduction was 18% (p = 0.07)
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trial. The mean mRSS score was 28 ± 10 (standard devi-
ation) at baseline visit and 30 ± 9 at week 8. Individual
mRSS scores for each patient are shown in Fig. 6. One of
the patients had digital ulcers at baseline and these healed
during the study. Four patients developed digital ulcers
during the study, and they healed in one of these patients
during the study. Only minor changes from baseline were
observed in SHAQ and SF-36 scores indicating no effect
on QoL measurements in this short trial.
Discussion
Paquinimod has shown disease inhibitory effects in a
number of experimental models of inflammation and
autoimmune diseases including models for SSc [23, 25,
27, 28, 38]. In these models, paquinimod was found to
affect the infiltration of myeloid cells into inflammatory
sites, implicating an effect of paquinimod on the innate
immune system.
In recent years, the innate immune system has been
recognized as a player in the pathogenesis of SSc. Ele-
vated levels of type I IFN, a key regulator of the innate
immune system, have been reported in SSc patients [12–
14], and IFN-regulated genes have been shown to con-
tribute to the prediction of skin fibrosis worsening [39].
The current open-label short-term clinical trial enrolled
9 SSc patients, all fulfilling the ACR 1980 classification
criteria with rapidly progressive disease. One of the pa-
tients enrolled in the current study presented elevated
Fig. 5 Changes of the number of myofibroblasts in skin biopsies from each individual patient treated with paquinimod. The myofibroblasts were
analyzed by immunohistochemistry and detected by using an antibody recognizing α-smooth muscle actin (αSMA) in skin biopsies taken at
baseline and week 8. The mean (shown in red) reduction was 8% (p = 0.023)
Table 2 Adverse events occurring more than once or in more than one patient
System organ class
Preferred term
Mild (%) Moderate (%) Severe (%) Total (%)
Gastrointestinal disorders
Diarrhea 2 (22)a 2 (22)a
Infections and infestations
Nasopharyngitis 2 (22) 2 (22)
Musculoskeletal and connective tissue disorders
Arthralgia 3 (33)b 3 (33)b
Arthritis 2 (22) 2 (22)
Myalgia 1 (11)a 1 (11)a 2 (22)a
Nervous system disorders
Headache 3 (33)b 3 (33)b
aRelated adverse events
bTwo out of 3 related adverse events
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type I IFN activity in the plasma at baseline. This is less
frequent than previously reported for SSc patients, which
might be due to the low number of patients in this study.
However, it should be noted that U1 small nuclear ribonu-
cleoprotein (U1-RNP) antibody-positive SSc patients have
the strongest increase in type I interferon signatures [40],
and U1-RNP antibody-positive patients were not recruited
into this study. Our results indicate that paquinimod
might reduce the type 1 IFN activity in SSc patients. In-
deed, after 4 weeks of treatment, a clear reduction was evi-
dent in the patient with increased type I IFN activity in
plasma and the activity then remained low throughout the
whole treatment period. This observation is in line with
observations from previous clinical studies with paquini-
mod in SLE patients [28, 32]. An effect of paquinimod on
type I IFN activity in the current SSc clinical study further
supported by the observed mean reduction of mRNA
levels of 5 different IFN regulated genes in skin biopsies
from patients treated with paquinimod. These 5 genes
were chosen since they have been reported to be upregu-
lated in SSc skin and blood and have been used as phar-
macodynamic biomarkers for monitoring response to
anti-IFN type I therapy in SSc [13, 41]. There has been
suggested to be an autocrine regulation of fibrosis via a
CCL2/CCR2 autocrine loop in early dcSSc, the target
population in the present study [37]. It is thus possible
that the reduction of CCR2 expression found after therapy
is beneficial. This is further supported by the fact that in
an experimental SSc model, the anti-fibrotic effect of
paquinimod was accompanied by reduced CCR2 mRNA
levels in response to paquinimod treatment [27].
The number of myofibroblasts, the main producers of
extracellular matrix proteins, has been suggested as a
biomarker for clinical outcome in SSc since they play an
important role in the pathogenesis of fibrosis and have
been reported to correlate with mRSS [42, 43]. The myo-
fibroblast count was reduced by 10% (p = 0.023) during
the 8 weeks of paquinimod treatment. It is challenging
to predict the magnitude of a potential clinical effect fol-
lowing a longer treatment period with paquinimod based
on the current data from 8 weeks of treatment. However,
the significant reduction of myofibroblasts seen in the
patients may indicate a pharmacological effect of paqui-
nimod in SSc patients. Especially, since the anti-fibrotic
effect of paquinimod in an experimental model of SSc
correlated with reduction of the number of myofibro-
blasts in the skin from mice [27].
The current open-label short-term clinical trial en-
rolled 9 SSc patients with rapidly progressive disease.
The treatment duration of 8 weeks was considered suffi-
cient to detect changes in biomarkers following treat-
ment. In addition, it was considered short enough to
avoid spontaneous improvement of biomarkers in pa-
tients with progressive disease. However, the study was
too short to expect changes in disease activity, e.g., by
mRSS, a common end-point in long-term placebo-
controlled SSc trials.
Paquinimod was well tolerated in the study, and the
reported AEs were mainly mild and transient and in line
with the AE profile observed in previous clinical paqui-
nimod studies [24]. Transient effects on laboratory
parameters, mainly related to elevated acute phase
Fig. 6 Modified Rodnan Skin Score (mRSS) at baseline, at weeks 4 and 8, and at follow-up in each individual patient treated with paquinimod
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reactants such as CRP and ESR, were observed. The
mechanism behind these transient increases is unknown,
and a possible relationship to clinical symptoms is un-
clear. Some patients reported mild to moderate arthral-
gias and arthritis, but a causal relationship with the
paquinimod-induced increased CRP levels is difficult to
prove in an open-label study, as joint inflammation is
part of the SSc spectrum. Increases in CRP levels have
also been reported in previous studies with paquinimod
[24]. In autoimmune diseases, such as SLE, there is
known to be a dissociation between innate immunity
and CRP levels, possibly due to CRP polymorphism
rs1205, which could also be possible in SSc [44]
The present study has some limitations. First, the
number of patients was small in this early proof of con-
cept trial. Particularly, patients with a type 1 interferon
signature, which is one of the main targets of paquini-
mod based on recent trials, were under-represented in
our study, making firm conclusions on the efficacy in
this subgroup difficult. Second, there was no control
group, and the observed changes of the biomarkers ver-
sus baseline could thus reflect the spontaneous course of
the disease, although this is not expected in a short trial
of only 8 weeks. In addition, there are no fully validated
biomarkers available for SSc that can predict a clinical
response despite interferon signature genes have been
proposed as an important contribution to the progres-
sion of skin fibrosis. Thus, the selection of biomarkers
remains subjective and is subject to false-positive results
because of multiple testing.
Having these limitations in mind, the results of this
study showed effects on relevant disease biomarkers
such as type I IFN activity and number of myofibro-
blasts, in line with previous preclinical data in inflamma-
tory and fibrotic animal models and/or data in SLE
patients. Paquinimod at 3 mg/day was mostly well toler-
ated with mild to moderate adverse events. Altogether,
the result from the present study warrants further con-
firmation in a randomized, controlled study setting in-
cluding a longer treatment period with paquinimod in
SSc patients. Patients with increased type 1 IFN signa-
tures might benefit most from this treatment.
Conclusions
Analysis of biomarkers before and after treatment sug-
gest reduced type I IFN activity in the serum and skin,
reduction of CCR2 gene expression, and reduced num-
ber of myofibroblasts in lesional skin. Paquinimod was
overall well tolerated with mild to moderate and ex-
pected AEs.
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